共查询到20条相似文献,搜索用时 15 毫秒
1.
Majdi Saada Ofer Kobo Jawed Polad Majdi Halabi Alexander J. J. IJsselmuiden ngel Puentes Jacques Monsgu David Austin Ruslan K. Baisebenov Fabrizio Span Ariel Roguin eULTIMASTER Investigators 《Clinical cardiology》2022,45(12):1211
BackgroundElderly patients with ST‐elevation myocardial infarction (STEMI) who undergo percutaneous coronary intervention (PCI) are usually excluded from major trials.HyopthesisThis study sought to assess 1‐year clinical outcomes following PCI with a drug‐eluting stent in patients older than 80 years old with STEMI.MethodsThe large all‐comer, multicontinental e‐ULTIMASTER registry included 7507 patients with STEMI who underwent PCI using the Ultimaster stent. The primary clinical endpoint was 1‐year target lesion failure, a composite of cardiac death (CD), target vessel‐related myocardial infarction (TV‐MI), or clinically driven target lesion revascularization (CD‐TLR).ResultsThere were 457 (6.1%) patients in the elderly group (≥80 years old) that were compared to 7050 (93.9%) patients <80 years. The elderly patients included more female patients and had significantly more comorbidities and had more complex coronary anatomy. The primary endpoint occurred in 7.2% of the elderly, compared to 3.1% of the younger group (p < .001). All‐cause mortality was significantly higher among the elderly group compared to the younger group (10.1% vs. 2.3%, p < .0001), as well as CD (6.1% vs. 1.6%, p < .0001), but not TV‐MI (1.1% vs. 0.7%, p = .34) or CD‐TLR (1.1% vs. 1.4%, p = .63).ConclusionElderly patients with STEMI presentation had a higher incidence of the composite endpoint than younger patients. All‐cause and CD were higher for elderly patients compared to patients younger than 80 years old. However, there was no difference in the incidence of TV‐MI or target lesion revascularizations. These findings suggest that PCI for STEMI in elderly patients is relatively safe. 相似文献
2.
Hanjun Zhao Zhaoxue Sheng Yu Tan Runzhen Chen Jinying Zhou Jiannan Li Qianyu Zhao Ying Wang Xiaoxiao Zhao Yi Chen Peng Zhou Chen Liu Li Song Hongbing Yan 《Journal of atherosclerosis and thrombosis》2022,29(10):1499
Aims: We previously associated acute ST-elevation myocardial infarction (STEMI) with decreased plasma LL-37 levels. Therefore, this study investigated whether plasma LL-37 levels could predict ischemic cardiovascular events in patients after STEMI. Methods: We prospectively collected peripheral plasma samples and clinical and laboratory data from consecutive patients who presented with STEMI and underwent primary percutaneous coronary intervention at Fuwai Hospital between April and November 2017. Enzyme-linked immunosorbent assay measured plasma LL-37 levels, and we followed the patients for 3 years. Major adverse cardiovascular events (MACEs) were a composite of all-cause mortality, reinfarction, unscheduled revascularization, or ischemic stroke. Results: The study included 302 patients divided into high (≥ median) and low LL-37 level (<median) groups. The cumulative incidence of MACE (29.1% vs. 12.6%, p=0.0003), all-cause death (12.6% vs. 3.3%, p=0.003), reinfarction (7.1% vs. 2.0%, p=0.04), and unscheduled revascularization (13.0% vs. 5.4%, p=0.04) were higher in the low than those in the high LL-37 level group. Multivariable Cox regression analysis showed that higher LL-37 level independently predicted lower risks of MACE (hazard ratio [HR] 0.390; 95% confidence interval [CI] 0.227–0.669; p<0.001), all-cause death (HR 0.324; 95%CI 0.119–0.879; p=0.027), and unscheduled revascularization (HR 0.391; 95%CI 0.171–0.907; p=0.027). Conclusions: High basal plasma level of human LL-37 may predict lower 3-year risks of ischemic cardiovascular events in patients after STEMI. 相似文献
3.
Surya Dharma Isman Firdaus Siska Suridanda Danny Dafsah A. Juzar Alexander J. Wardeh J. Wouter Jukema Arnoud van der Laarse 《The International journal of angiology》2014,23(3):207-214
The appropriate timing of eptifibatide initiation for acute ST segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) remains unclear. This study aimed to analyze the impact of timing of eptifibatide administration on infarct-related artery (IRA) patency in STEMI patients undergoing primary PCI. Acute STEMI patients who underwent primary PCI (n = 324) were enrolled in this retrospective study; 164 patients received eptifibatide bolus ≤ 30 minutes after emergency department (ED) admission (group A) and 160 patients received eptifibatide bolus > 30 minutes after ED admission (group B). The primary endpoint was preprocedural IRA patency. Most patients in group A (90%) and group B (89%) were late presenters (> 2 hours after symptom onset). The two groups had similar preprocedural thrombolysis in myocardial infarction 2 or 3 flow of the IRA (26 vs. 24%, p = not significant [NS]), similar creatine kinase-MB (CK-MB) levels at 8 hours after admission (339 vs. 281 U/L, p = NS), similar left ventricular ejection fraction (LVEF) (52 vs. 50%, p = NS), and similar 30-day mortality (2 vs. 7%, p = NS). Compared with group B, patients in group A had shorter door-to-device time (p < 0.001) and shorter procedural time (p = 0.004), without increased bleeding risk (13 vs. 18%, p = NS). Earlier intravenous administration of eptifibatide before primary PCI did not improve preprocedural IRA patency, CK-MB level at 8 hours after admission, LVEF and 30-day mortality compared with patients who received intravenous eptifibatide that was administered later. 相似文献
4.
Qian Yu Dawei Guo Jianan Peng Qifei Wu Yonghuan Yao Mei Ding Jiang Wang 《Clinical cardiology》2023,46(1):5
BackgroundThe association between frailty and older patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI) is unclear. Therefore, we conducted a systematic review and meta‐analysis to investigate the prevalence of frailty in older patients with AMI following PCI, and determine the relationship between frailty and adverse outcomes in these patients.HypothesisOlder patients with AMI have a higher prevalence of frailty after PCI, and the frailty in these patients increases the risk of adverse outcomes.MethodsA comprehensive search of the PubMed, Cochrane, Ovid (Medline), Ovid (Embase), and Web of Science databases was performed for articles published until October 2021. A meta‐analysis was performed using stata12.0 software. A random‐effects model was used when I 2 was greater than 50%; otherwise, a fixed‐effects model was used.ResultsThere were a total of 274,976 older patients in the included studies. Nine studies investigated the prevalence of frailty in older patients with AMI after PCI, with an overall prevalence of 39% (95% confidence interval [CI]: 18%–60%, p < .001). Six studies included adverse outcomes of frailty in older patients with AMI after PCI, including all‐cause mortality (hazard ratio [HR] = 2.29, 95% CI: 1.65–3.16, p = .285), rehospitalization (HR = 2.53, 95% CI: 1.38–4.63), and in‐hospital major bleeding (HR = 1.93, 95% CI: 1.29–2.90, p = .825).ConclusionThe frailty prevalence is increased in older patients with AMI after PCI, especially in ST‐segment elevation myocardial infarction (STEMI). AMI with frailty after PCI is more likely to be associated with worse clinical outcomes, such as death, bleeding, and rehospitalization. 相似文献
5.
Surya Dharma Alexander J. Wardeh Sunarya Soerianata Isman Firdaus J Wouter Jukema 《The International journal of angiology》2014,23(2):93-100
The objective of this study is to determine the efficacy and safety of an everolimus-eluting stent (EES/Xience; Abbott Vascular, Santa Clara, CA) compared with a cobalt chromium stent (CoCr/Multi-Link Vision; Abbott Vascular) in patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) with routine administration of eptifibatide infusion. This is a prospective, single center, randomized trial comparing EES (n = 75) and CoCr stent (n = 75) implantation in patients with acute STEMI undergoing primary PCI. Intravenous eptifibatide administration was mandatory by protocol in this pilot study. The primary efficacy endpoint was major adverse cardiac events (MACE) at 30 days, defined as the composite of death, reinfarction, and target vessel revascularization. Secondary safety endpoints were stent thrombosis at 30 days and in-hospital bleeding event. Acute reperfusion parameters were also assessed. One-month MACE rate did not differ between EES and CoCr group (1.3 vs. 1.3%, p = 1.0). No stent thrombosis cases were observed in the EES group. The groups did not differ with respect to in-hospital bleeding events (5 vs. 9%, p = 0.37), achievement of final thrombolysis in myocardial infarction flow 2 or 3 (p = 0.21), achievement of myocardial blush grade 2 or 3 (p = 0.45), creatine kinase-MB level at 8 to 12 hours after stenting (p = 0.29), and left ventricular ejection fraction (p = 0.21). This pilot study demonstrates that after one-month follow-up, the use of EES is as safe and effective as the use of CoCr stents in patients with acute STEMI undergoing primary PCI with routine administration of intravenous eptifibatide. 相似文献
6.
Karam R. Motawea Hamed Gaber Ravi B. Singh Sarya Swed Salem Elshenawy Nesreen Elsayed Talat Nawal Elgabrty Sheikh Shoib Engy A. Wahsh Pense Chbl Sarraa M. Reyad Samah S. Rozan Hani Aiash 《Clinical cardiology》2022,45(10):1011
AimThis meta‐analysis aims to look at the impact of early intravenous Metoprolol in ST‐segment elevation myocardial infarction (STEMI) before percutaneous coronary intervention (PCI) on infarct size, as measured by cardio magnetic resonance (CMR) and left ventricular ejection fraction.MethodsWe searched the following databases: PubMed, Scopus, Cochrane library, and Web of Science. We included only randomized control trials that reported the use of early intravenous Metoprolol in STEMI before PCI on infarct size, as measured by CMR and left ventricular ejection fraction. RevMan software 5.4 was used for performing the analysis.ResultsFollowing a literature search, 340 publications were found. Finally, 18 studies were included for the systematic review, and 8 clinical trials were included in the meta‐analysis after the full‐text screening. At 6 months, the pooled effect revealed a statistically significant association between Metoprolol and increased left ventricular ejection fraction (LVEF) (%) compared to controls (mean difference [MD] = 3.57, [95% confidence interval [CI] = 2.22–4.92], p < .00001), as well as decreased infarcted myocardium(g) compared to controls (MD = −3.84, [95% [CI] = −5.75 to −1.93], p < .0001). At 1 week, the pooled effect revealed a statistically significant association between Metoprolol and increased LVEF (%) compared to controls (MD = 2.98, [95% CI = 1.26−4.69], p = .0007), as well as decreased infarcted myocardium(%) compared to controls (MD = −3.21, [95% CI = −5.24 to −1.18], p = .002).ConclusionA significant decrease in myocardial infarction and increase in LVEF (%) was linked to receiving Metoprolol at 1 week and 6‐month follow‐up. 相似文献
7.
Jonathan Beaudoin Jean-Pierre Dery Philippe Lachance Olivier F. Bertrand Eric Larose Josep Rods-Cabau Bernard Noël Grald Barbeau Guy Proulx Can Nguyen Louis Roy Onil Gleeton Stphane Rinfret Robert Delarochellire 《Cardiovascular Revascularization Medicine》2010,11(4):692-222
BackgroundPrimary percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI) may be limited by thrombus embolization. Export aspiration catheter (EAC) is a thrombectomy device which may enhance angiographic results, but its impact on clinical outcomes is unclear. This trial objective was to assess the impact of EAC on angiographic and clinical outcomes in patients with STEMI.MethodsAll STEMI patients undergoing primary or rescue PCI in a tertiary care center were included. Patients were divided in two groups according to the use of the EAC. Patients were followed up prospectively for death, reinfarction, revascularization, or stroke. Thrombolysis In Myocardial Infarction (TIMI) flow in the culprit vessel was assessed before and after PCI.ResultsIncluded in the analysis were 535 patients. EAC was used in 165 patients before angioplasty (Group 1) and 370 patients underwent PCI without thrombus aspiration (Group 2). More patients in Group 1 had initial TIMI flow 0–1 compared to Group 2 (88% vs. 62%, P<.001). Proportion of patients with a final TIMI flow 3 was the same in both groups (89.1% vs. 87.6% for Groups 1 and 2, respectively; P=.67). An analysis restricted to patients with initial TIMI flow 0–1 yielded similar results. No difference in clinical outcomes was observed between the two groups (P=.70).ConclusionsSelective use of the EAC based on the judgment of operators results in excellent angiographic and clinical results. Further clinical investigation is needed to definitely answer whether thromboaspiration needs to be performed in all STEMI patients undergoing primary PCI. 相似文献
8.
Takamasa Tanaka Kojiro Miki Hirokuni Akahori Takahiro Imanaka Nagataka Yoshihara Toshio Kimura Koji Yanaka Masanori Asakura Masaharu Ishihara 《Clinical cardiology》2021,44(2):238
BackgroundPatients with non‐ST‐elevation myocardial infarction (NSTEMI) have worse long‐term prognoses than those with ST‐elevation myocardial infarction (STEMI).HypothesisIt may be attributable to more extended coronary atherosclerotic disease burden in patients with NSTEMI.MethodsThis study consisted of consecutive 231 patients who underwent coronary intervention for myocardial infarction (MI). To assess the extent and severity of atherosclerotic disease burden of non‐culprit coronary arteries, two scoring systems (Gensini score and synergy between percutaneous coronary intervention with Taxus and cardiac surgery [SYNTAX] score) were modified by subtracting the score of the culprit lesion: the non‐culprit Gensini score and the non‐culprit SYNTAX score.ResultsPatients with NSTEMI had more multi‐vessel disease, initial thrombolysis in myocardial infarction (TIMI) flow grade 2/3, and final TIMI flow grade 3 than those with STEMI. As compared to STEMI, patients with NSTEMI had significantly higher non‐culprit Gensini score (16.3 ± 19.8 vs. 31.2 ± 25.4, p < 0.001) and non‐culprit SYNTAX score (5.8 ± 7.0 vs. 11.1 ± 9.7, p < 0.001).ConclusionsPatients with NSTEMI had more advanced coronary atherosclerotic disease burden including non‐obstruction lesions, which may at least in part explain higher incidence of cardiovascular events in these patients. 相似文献
9.
Charles Knoery Katie. A. McEwan Matthew Manktelow Jonathan Watt Jamie Smith Aleeha Iftikhar Khaled Rjoob Raymond Bond Victoria McGilligan Aaron Peace Anne McShane Janet Heaton Stephen J. Leslie 《Clinical cardiology》2022,45(2):231
BackgroundTreatment decisions in myocardial infarction (MI) are currently stratified by ST elevation (ST‐elevation myocardial infarction [STEMI]) or lack of ST elevation (non‐ST elevation myocardial infarction [NSTEMI]) on the electrocardiogram. This arose from the assumption that ST elevation indicated acute coronary artery occlusion (OMI). However, one‐quarter of all NSTEMI cases are an OMI, and have a higher mortality. The purpose of this study was to identify features that could help identify OMI.MethodsProspectively collected data from patients undergoing percutaneous coronary intervention (PCI) was analyzed. Data included presentation characteristics, comorbidities, treatments, and outcomes. Latent class analysis was undertaken, to determine patterns of presentation and history associated with OMI.ResultsA total of 1412 patients underwent PCI for acute MI, and 263 were diagnosed as OMI. Compared to nonocclusive MI, OMI patients are more likely to have fewer comorbidities but no difference in cerebrovascular disease and increased acute mortality (4.2% vs. 1.1%; p < .001). Of OMI, 29.5% had delays to their treatment such as immediate reperfusion therapy. With latent class analysis, while clusters of similar patients are observed in the data set, the data available did not usefully identify patients with OMI compared to non‐OMI.ConclusionFeatures between OMI and STEMI are broadly very similar. However, there was no difference in age and risk of cerebrovascular disease in the OMI/non‐OMI group. There are no reliable characteristics therefore for identifying OMI versus non‐OMI. Delays to treatment also suggest that OMI patients are still missing out on optimal treatment. An alternative strategy is required to improve the identification of OMI patients. 相似文献
10.
Julia Stehli Diem Dinh Misha Dagan Ron Dick Stephanie Oxley Angela Brennan Jeffrey Lefkovits Stephen J. Duffy Sarah Zaman 《Clinical cardiology》2022,45(4):427
Background and HypothesisTwo cohorts face high mortality after ST‐elevation myocardial infarction (STEMI): females and patients with in‐hospital STEMI. The aim of this study was to evaluate sex differences in ischemic times and outcomes of in‐hospital STEMI patients.MethodsConsecutive STEMI patients treated with percutaneous coronary intervention (PCI) were prospectively recruited from 30 hospitals into the Victorian Cardiac Outcomes Registry (2013−2018). Sex discrepancies within in‐hospital STEMIs were compared with out‐of‐hospital STEMIs. The primary endpoint was 12‐month all‐cause mortality. Secondary endpoints included symptom‐to‐device (STD) time and 30‐day major adverse cardiovascular events (MACE). To investigate the relationship between sex and 12‐month mortality for in‐hospital versus out‐of‐hospital STEMIs, an interaction analysis was included in the multivariable models.ResultsA total of 7493 STEMI patients underwent PCI of which 494 (6.6%) occurred in‐hospital. In‐hospital versus out‐of‐hospital STEMIs comprised 31.9% and 19.9% females, respectively. Female in‐hospital STEMIs were older (69.5 vs. 65.9 years, p = .003) with longer adjusted geometric mean STD times (104.6 vs. 94.3 min, p < .001) than men. Female versus male in‐hospital STEMIs had no difference in 12‐month mortality (27.1% vs. 20.3%, p = .92) and MACE (22.8% vs. 19.3%, p = .87). Female sex was not independently associated with 12‐month mortality for in‐hospital STEMIs which was consistent across the STEMI cohort (OR: 1.26, 95% CI: 0.94–1.70, p = .13).ConclusionsIn‐hospital STEMIs are more frequent in females relative to out‐of‐hospital STEMIs. Despite already being under medical care, females with in‐hospital STEMIs experienced a 10‐min mean excess in STD time compared with males, after adjustment for confounders. Adjusted 12‐month mortality and MACE were similar to males. 相似文献
11.
Yong Hoon Kim Ae-Young Her Myung Ho Jeong Byeong-Keuk Kim Sung-Jin Hong Seung-Jun Lee Chul-Min Ahn Jung-Sun Kim Young-Guk Ko Donghoon Choi Myeong-Ki Hong Yangsoo Jang 《Medicine》2021,100(49)
We compared the 2-year major clinical outcomes between ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) in patients who are current smokers who underwent successful percutaneous coronary intervention (PCI) with newer-generation drug-eluting stents (DESs). The availability of data in this regard is limited.A total of 8357 AMI patients were included and divided into 2 groups: the STEMI group (n = 5124) and NSTEMI group (n = 3233). The primary endpoint was the occurrence of major adverse cardiac events (MACE), defined as all-cause death, recurrent myocardial infarction (re-MI), or coronary repeat revascularization. The secondary endpoints were the cumulative incidences of the individual components of MACE and stent thrombosis (definite or probable).After propensity score-matched (PSM) analysis, 2 PSM groups (2250 pairs, C-statistics = 0.795) were generated. In the PSM patients, both for 1 month and at 2 years, the cumulative incidence of MACE (P = .183 and P = .655, respectively), all-cause death, cardiac death, re-MI, all-cause death or MI, any repeat revascularization, and stent thrombosis (P = .998 and P = .341, respectively) was not significantly different between the STEMI and NSTEMI groups. In addition, these results were confirmed using multivariate analysis.In the era of contemporary newer-generation DESs, both during 1 month and at 2 years after index PCI, the major clinical outcomes were not significantly different between the STEMI and NSTEMI groups confined to the patients who are current smokers. However, further research is needed to confirm these results. 相似文献
12.
目的:探讨血栓抽吸术对急性ST段抬高心肌梗死患者预后的影响。方法:回顾性分析2013年1月至2015年2月于上海市胸科医院就诊发病时间<12小时的急性ST段抬高心肌梗死患者257例,所有患者均进行急诊PCI治疗。最终完成1年随访的患者中121例患者进行血栓抽吸术,136例患者进行直接PCI。随访两组患者30天、1年的MACE事件及心功能。结果:两组患者在30天(3.3% vs 5.1%, P=0.548)、1年的MACE事件(5.7% vs 8.8%, P=0.475)发生率上没有显著差异。虽然即刻TIMI 3级血流比例两组同样没有差异(72.7% vs 69.9%, P=0.679),但两组在NYHA III-IV心衰的比例30天随访(15% vs 26.3%, P=0.044)、1年随访(5.0% vs 12.9%, P=0.047)血栓抽吸组均显著降低。结论:血栓抽吸术对心血管主要不良事件无显著影响,但对于降低远期心衰的发作仍具有重要作用。 相似文献
13.
延迟冠状动脉介入治疗与静脉溶栓后药物保守治疗的对比研究 总被引:2,自引:0,他引:2
目的 评价静脉溶栓治疗后常规行延迟冠状动脉介入 (PCI)的价值。方法 对 98例ST段抬高性心肌梗死 (STEMI)患者常规行延迟PCI,然后与既往行静脉溶栓后药物保守治疗的 82例患者对照观察住院期间和随访 6个月时的临床不良事件和超声心动图的变化。所有患者分为对照组 (静脉溶栓后保守治疗 )、试验 1组 (静脉溶栓成功后行延迟PCI)和试验 2组 (静脉溶栓失败后行延迟PCI)。结果 与静脉溶栓保守治疗比较 ,静脉溶栓后常规施行延迟PCI可以降低住院期间的死亡率(4 9%vs 0 % ,0 % )、缩短平均住院时间 (2 5 3dvs13 5d ,15 1d)、减少对靶病变血管重建治疗的需要(7 3%vs 0 % ,0 % )和降低血栓形成或心肌梗死的发生率 (7 3%vs 0 % ,0 % ) ,还可以明显降低 6个月死亡率 (13 4 %vs 1 4 % ,0 % )、减少再次心肌梗死 (12 2 %vs 4 2 % ,4 5 % )和卒中 (2 4 %vs 0 % ,0 % )的发生、减少因缺血做靶血管重建治疗 (2 8%vs 4 2 % ,4 5 % )和防止左室进一步发生重塑。结论 常规施行延迟PCI可以防止再发性缺血、再次梗死和梗死相关动脉再闭塞和改善左室功能 ,因而提高住院期间和 6个月的治疗效果。 相似文献
14.
Yosuke Kawamura Hiroaki Yokoyama Kazutaka Kitayama Naotake Miura Misato Hamadate Daiki Nagawa Masashi Nozaka Masamichi Nakata Fumie Nishizaki Kenji Hanada Takashi Yokota Masahiro Yamada Takumi Higuma Hirofumi Tomita 《Clinical cardiology》2021,44(1):91-99
Complete atrioventricular block (CAVB) is a common complication of ST‐segment elevation myocardial infarction (STEMI). Although STEMI patients complicated with CAVB had a higher mortality in the thrombolytic era, little is known about the impact of CAVB on STEMI patients who underwent primary percutaneous coronary intervention (PCI). The study aimed at evaluating the clinical impact of CAVB on STEMI patients in the primary PCI era. We consecutively enrolled 1295 STEMI patients undergoing primary PCI within 24 hours from onset. Patients were divided into two groups according to the infarct location: anterior STEMI (n = 640) and nonanterior STEMI (n = 655). The outcomes were all‐cause death and major adverse cardiocerebrovascular events (MACCE) with a median follow‐up period of 3.8 (1.7–6.6) years. Eighty‐one patients (6.3%) developed CAVB. The incidence of CAVB was lower in anterior STEMI patients than in nonanterior STEMI (1.7% vs 10.7%, p < .05). Anterior STEMI patients with CAVB had a higher incidence of all‐cause deaths (82% vs 20%, p < .05) and MACCE (82% vs 25%, p < .05) than those without CAVB. Although higher incidence of all‐cause deaths was found more in nonanterior STEMI patients with CAVB compared with those without CAVB (30% vs 18%, p < .05), there was no significant difference in the incidence of MACCE (24% vs 19%). Multivariate analysis showed that CAVB was an independent predictor for all‐cause mortality and MACCE in anterior STEMI patients, but not in nonanterior STEMI. CAVB is rare in anterior STEMI patients, but remains a poor prognostic complication even in the primary PCI era. 相似文献
15.
Percoco G Manari A Guastaroba P Campo G Guiducci V Aurier E Sangiorgio P Passerini F Geraci G Piovaccari G Naldi M Saia F Marzocchi A;Real Investigators 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2006,20(1):63-68
Summary Background: Limited data are available for sirolimus eluting stent (SES) implantation in patients with ST-segment elevation myocardial
infarction (STEMI). Aim: to confirm the safety and effectiveness of SES in patients with STEMI in a real-world scenario (multicentric registry).
Methods: From July 2002 to June 2004, clinical and angiographic data of 1617 patients with STEMI treated with primary percutaneous
coronary intervention (PCI) have been collected. Patients were prospectively followed for the occurrence of major adverse
cardiac events (MACE): death, reinfarction and target vessel revascularization (TVR). Results: Overall, 205 patients received SES (12.5%, SES group) and 1412 received bare metal stent (87.5%, BMS group) in the infarct
related artery. Compared with the BMS group, SES patients were younger, had more often diabetes mellitus, anterior localization
and less cardiogenic shock at admission. The angiographic characteristics in the SES group showed longer lesions and smaller
diameter of vessels. After a median follow-up of 396 days, there was no significant difference in the rate of stent thrombosis
(1% in the SES group vs 1.5% in the BMS group, p=ns). The incidence of MACE was significantly lower in the SES group compared to BMS group (HR 0.62 [95% CI: 0.4–0.95]; p=0.03), principally due to the lower rate of TVR (HR 0.41 [95% CI: 0.2–0.85]; p=0.01). Conclusions: Utilization of SES in the setting of primary PCI for STEMI, in our “real world” registry, was safe and improved the 1-year
clinical outcome compared to BMS reducing the need of TVR. 相似文献
16.
Erin RaynerHartley Graham C. Wong Cassandra Fayowski John A. Cairns Joel Singer Terry Lee Tara Sedlak Karin H. Humphries Michele PerryArnesen Martha Mackay Christopher B. Fordyce 《Clinical cardiology》2021,44(8):1113
BackgroundWomen with ST‐elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention historically experience worse in‐hospital outcomes compared to men.HypothesisImplementation of a regional STEMI system will reduce care gaps in reperfusion times and in‐hospital outcomes between women and men.Methods1928 patients (413 women, 21.4%) presented with an acute STEMI between June 2007 and March 2016. The population was divided into an early cohort (n = 728 patients, 2007‐May 2011), and a late cohort (n = 1200 patients, June 2011–2016). The primary endpoints evaluated were reperfusion times and in‐hospital outcomes.ResultsCompared to men, women experienced significant delays in first medical contact (FMC) to arrival at the emergency room (26.0 vs. 22.0 min, p < 0.001) and FMC‐to‐device (109 vs. 101 min p = 0.001). Women had higher incidences of post‐PCI heart failure and death compared to men (p < 0.05). Following multivariable adjustment, no mortality difference was observed for women versus men (adjusted OR; 0.82; 95% confidence interval [CI], 0.51–1.34; p = 0.433) or for early versus late cohorts (adjusted OR; 1.04; 95% CI, 0.68–1.60; p = 0.856).ConclusionFollowing STEMI regionalization, women continued to experience significantly longer reperfusion times, although there was no difference in adjusted mortality. These results highlight the ongoing disparity of STEMI care between women and men, and suggest that regionalization alone is insufficient to close sex‐based care gaps. 相似文献
17.
Anwar Santoso Yulianto Yulianto Hendra Simarmata Abhirama Nofandra Putra Erlin Listiyaningsih 《The International journal of angiology》2021,30(1):22
Major adverse cardio-cerebrovascular events (MACCE) in ST-segment elevation myocardial infarction (STEMI) are still high, although there have been advances in pharmacology and interventional procedures. Proprotein convertase subtilisin/Kexin type 9 ( PCSK9 ) is a serine protease regulating lipid metabolism associated with inflammation in acute coronary syndrome. The MACCE is possibly related to polymorphisms in PCSK9 . A prospective cohort observational study was designed to confirm the association between polymorphism of E670G and R46L in the PCSK9 gene with MACCE in STEMI. The Cox proportional hazards model and Spearman correlation were utilized in the study. The Genotyping of PCSK9 and ELISA was assayed. Sixty-five of 423 STEMI patients experienced MACCE in 6 months. The E670G polymorphism in PCSK9 was associated with MACCE (hazard ratio = 45.40; 95% confidence interval: 5.30–390.30; p = 0.00). There was a significant difference of PCSK9 plasma levels in patients with previous statin consumption (310 [220–1,220] pg/mL) versus those free of any statins (280 [190–1,520] pg/mL) ( p = 0.001). E670G polymorphism of PCSK9 was associated with MACCE in STEMI within a 6-month follow-up. The plasma PCSK9 level was higher in statin users. 相似文献
18.
目的探讨延迟经皮冠状动脉介入治疗(PC I)对急性心肌梗死(AM I)患者预后的影响。方法对38例ST段抬高的AM I患者经静脉溶栓后常规行延迟PC I(延迟组),然后与经静脉溶栓后药物保守治疗(对照组)的34例患者进行对比分析,观察住院期间和随访6个月时的临床不良事件和超声心动图的变化。结果与保守治疗比较,常规施行延迟PC I可以降低住院期间的病死率(0%vs15%,P<0.05),缩短平均住院时间(15 dvs28 d,P<0.05),减少住院期间心绞痛发作(5%vs35%,P<0.05)及再次心肌梗死(0%vs9%,P<0.05);还可以明显降低6个月病死率(3%vs12%,P<0.05)和再住院率(8%vs26%,P<0.05),防止左心室进一步重构,改善患者心脏功能。结论常规施行延迟PC I可以提高AM I患者住院期间和6个月的治疗效果,改善临床预后。 相似文献
19.
Etienne Puymirat Ariel Nakache Christophe Saint Etienne Pierre Marcollet Olivier Fichaux MariePascale Decomis Stephan Chassaing Philippe Commeau Nicolas Danchin Guillaume Cayla Gilles Montalescot Hakim Benamer Rene Koning Pascal Motreff Grgoire Rang 《Clinical cardiology》2021,44(3):429
BackgroundST‐elevation myocardial infarction (STEMI) patients with multivessel disease (MVD) are associated with a worse prognosis. However, few comparisons are available according to coronary status in the era of modern reperfusion and optimized secondary prevention.HypothesisWe hypothesized that the difference in prognosis according to number of vessel disease in STEMI patients has reduced.MethodsAll consecutive STEMI patients undergoing primary percutaneous coronary intervention (PCI) within 24 h of symptoms onset between January 1, 2014 and June 30, 2016 enrolled in the CRAC (Club Régional des Angioplasticiens de la région Centre) France PCI registry were analyzed. Baseline characteristics, management, and outcomes at 1‐year were analyzed according to coronary status (one‐, two‐, and three‐VD).ResultsA total of 1886 patients (mean age 62.2 ± 14.0 year; 74% of male) were included. Patients with MVD (two or three‐VD) represented 53.7%. They were older with higher cardiovascular risk factor profile. At 1 year, the rate of major adverse cardiovascular events (MACE, defined as all‐cause death, stroke or re‐MI) was 10%, 12%, and 12% in one‐, two, and three‐VD respectively (p = .28). In multivariable adjusted Cox proportional hazard regression model, two‐ and three‐VD were not associated with higher rate of MACE compared to patients with single VD (HR, 1.09; 95%CI 0.76–1.56 for two‐VD; HR, 0.74; 95%CI 0.48–1.14 for three‐VD).ConclusionsMVD still represents an important proportion of STEMI patients but their prognoses were not associated with worse clinical outcomes at 1‐year compared with one‐VD patients in a modern reperfusion area and secondary medication prevention. 相似文献
20.
Surya Dharma Iwan Dakota Isman Firdaus Siska Suridanda Danny Dian Zamroni Ardi Yudha Agus Susanto Bambang Budi Siswanto 《The International journal of angiology》2021,30(2):148
There has been concern whether the declining cases of ST-segment elevation myocardial infarction (STEMI) during the coronavirus disease 2019 (COVID-19) outbreak associate with primary angioplasty performance.We assessed the performance of primary angioplasty in a tertiary care hospital in Jakarta, Indonesia, by comparing the door-to-device (DTD) time and thrombolysis in myocardial infarction (TIMI) flow after angioplasty between two periods of admission: during the outbreak of COVID-19 (March 1 to May 31, 2020) and before the outbreak (March 1, to May 31, 2019). Overall, there was a relative reduction of 44% for STEMI admission during the outbreak ( n = 116) compared with before the outbreak ( N = 208). Compared with before the outbreak period ( n = 141), STEMI patients who admitted during the outbreak and received primary angioplasty ( n = 70) had similar median symptom onset-to-angioplasty center admission (360 minutes for each group), similar to radial access uptake (90 vs. 89.4%, p = 0.88) and left anterior descending infarct-related artery (54.3 vs. 58.9%, p = 0.52). The median DTD time and total ischemia time were longer (104 vs. 81 minutes, p < 0.001, and 475.5 vs. 449 minutes, p = 0.43, respectively). However, the final achievement of TIMI 3 flow was similar (87.1 vs. 87.2%), and so was the in-hospital mortality (5.7 vs. 7.8%). During the COVID-19 outbreak, we found a longer DTD time for primary angioplasty, but the achievement of final TIMI 3 flow and in-hospital mortality were similar as compared with before the outbreak. Thus, primary angioplasty should remain the standard of care for STEMI during the COVID-19 outbreak. 相似文献